Evidence map›Paper›PMID 41767520›Full record

ArticleFrontiers in medicine2026

Clinical and histopathological features of chronic hepatitis B with normal alanine aminotransferase levels with or without concomitant non-alcoholic fatty liver disease.

Wencong Li, Shiheng Liu, Weiguang Ren, Xiaoxiao Zhang, Lingdi Liu, Fang Han, Ying Zhang, Yuemin Nan, Suxian Zhao

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Wencong Li *Department of Traditional and Western Medical Hepatology, Hebei Medical University Third Hospital, the Key Laboratory of Hepatic Fibrosis Mechanisms of Chronic Liver Diseases in Hebei Province, HebeiInternational Science and Technology Cooperation Base - Hebei International Joint Research Center for Molecular Diagnosis of Liver Cancer, Shijiazhuang, China.
Shiheng Liu *Department of Traditional and Western Medical Hepatology, Hebei Medical University Third Hospital, the Key Laboratory of Hepatic Fibrosis Mechanisms of Chronic Liver Diseases in Hebei Province, HebeiInternational Science and Technology Cooperation Base - Hebei International Joint Research Center for Molecular Diagnosis of Liver Cancer, Shijiazhuang, China.
Weiguang RenDepartment of Traditional and Western Medical Hepatology, Hebei Medical University Third Hospital, the Key Laboratory of Hepatic Fibrosis Mechanisms of Chronic Liver Diseases in Hebei Province, HebeiInternational Science and Technology Cooperation Base - Hebei International Joint Research Center for Molecular Diagnosis of Liver Cancer, Shijiazhuang, China.
Xiaoxiao ZhangDepartment of Traditional and Western Medical Hepatology, Hebei Medical University Third Hospital, the Key Laboratory of Hepatic Fibrosis Mechanisms of Chronic Liver Diseases in Hebei Province, HebeiInternational Science and Technology Cooperation Base - Hebei International Joint Research Center for Molecular Diagnosis of Liver Cancer, Shijiazhuang, China.
Lingdi LiuDepartment of Traditional and Western Medical Hepatology, Hebei Medical University Third Hospital, the Key Laboratory of Hepatic Fibrosis Mechanisms of Chronic Liver Diseases in Hebei Province, HebeiInternational Science and Technology Cooperation Base - Hebei International Joint Research Center for Molecular Diagnosis of Liver Cancer, Shijiazhuang, China.
Fang HanDepartment of Traditional and Western Medical Hepatology, Hebei Medical University Third Hospital, the Key Laboratory of Hepatic Fibrosis Mechanisms of Chronic Liver Diseases in Hebei Province, HebeiInternational Science and Technology Cooperation Base - Hebei International Joint Research Center for Molecular Diagnosis of Liver Cancer, Shijiazhuang, China.
Ying ZhangDepartment of Traditional and Western Medical Hepatology, Hebei Medical University Third Hospital, the Key Laboratory of Hepatic Fibrosis Mechanisms of Chronic Liver Diseases in Hebei Province, HebeiInternational Science and Technology Cooperation Base - Hebei International Joint Research Center for Molecular Diagnosis of Liver Cancer, Shijiazhuang, China.
Yuemin NanDepartment of Traditional and Western Medical Hepatology, Hebei Medical University Third Hospital, the Key Laboratory of Hepatic Fibrosis Mechanisms of Chronic Liver Diseases in Hebei Province, HebeiInternational Science and Technology Cooperation Base - Hebei International Joint Research Center for Molecular Diagnosis of Liver Cancer, Shijiazhuang, China.
Suxian ZhaoDepartment of Traditional and Western Medical Hepatology, Hebei Medical University Third Hospital, the Key Laboratory of Hepatic Fibrosis Mechanisms of Chronic Liver Diseases in Hebei Province, HebeiInternational Science and Technology Cooperation Base - Hebei International Joint Research Center for Molecular Diagnosis of Liver Cancer, Shijiazhuang, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: To analyze the clinical and hepatic pathological characteristics of patients with chronic hepatitis B (CHB) alone or with non-alcoholic fatty liver disease (NAFLD), who have normal alanine aminotransferase (ALT) levels. Methods: The patients with normal ALT levels and pathologically diagnosed CHB alone or in combination with NAFLD were enrolled, the demographic, laboratory, and pathological data were collected and analyzed. Results: Among 391 enrolled CHB patients with normal ALT levels, 107 individuals combined with NAFLD. The incidence of significant liver injury (G and/or S ≥ 2) in patients with CHB alone was lower significantly than that of patients with CHB and NAFLD (64.08% vs. 78.50%, Conclusion: Patients with normal ALT can still demonstrate significant liver tissue damage. The combination of NAFLD will significantly increase the incidence of significant liver injury in patients with CHB, especially in those who are HBeAg positive, male, over 30 years old.

Indexed as

alanine aminotransferasechronic hepatitis BHBcAgnon-alcoholic fatty liver diseasepathology

Identifiers

PMID41767520
PMCPMC12935996

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.